SCHEMBL25035657

SCHEMBL25035657

BC1(B)C(Cn2cc(-c3ncnc(N)c3CC(OCC)OCC)cn2)C(B)(O)C(B)(B)C1(B)O

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.30
JAK3 P52333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035775 0.85 JAK3 (0.31) JAK2JAK3
SCHEMBL25034415 0.84 JAK3 (0.32) JAK2JAK3
SCHEMBL25035763 0.84 JAK3 (0.32) JAK2JAK3
SCHEMBL22343496 0.80 JAK3 (0.32) JAK2JAK3
SCHEMBL25035730 0.78 LRRK2 (0.39) JAK2JAK3
SCHEMBL25034420 0.78 JAK2 (0.32) JAK2JAK3
SCHEMBL24599467 0.73 JAK2 (0.39) JAK2JAK3
SCHEMBL25035651 0.71 JAK3 (0.32) JAK2JAK3
SCHEMBL25035693 0.69
SCHEMBL22343519 0.68 JAK3 (0.41) JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023018954-A1 TREATMENT OF JAK-INHIBITION-RESPONSIVE DISORDERS WITH PRODRUGS OF JAK INHIBITORS CONCERT PHARMACEUTICALS, INC. (US) 2023-02-16 WO disclosed